| Bioactivity | Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy[1]. |
| Target | VEGF |
| Invitro | Arginyl-Glutamine (0.5-1.5 mM; 48 h) 会导致人类 RPE 细胞中可溶性 VEGF 在培养基中的表达呈统计学意义上的剂量依赖性下降[1]。 |
| In Vivo | Arginyl-Glutamine (1-5 g/kg/day as a hydrochloride salt; i.p.; twice daily) 显著抑制小鼠氧诱导视网膜病变 (OIR) 模型中的视网膜新生血管[1]。 Animal Model: |
| Name | Arginyl-Glutamine |
| CAS | 2483-17-2 |
| Sequence | Arg-Gln |
| Shortening | RQ |
| Formula | C11H22N6O4 |
| Molar Mass | 302.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Neu J, et al. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3151-5. |
Arginyl-Glutamine
CAS: 2483-17-2 F: C11H22N6O4 W: 302.33
Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model o
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.